ImCheck Therapeutics Presents Key Data on AML Treatment
Marseille, France – ImCheck Therapeutics is set to showcase groundbreaking data related to its lead candidate, ICT01, during an oral presentation at the upcoming annual conference of a prominent hematology organization. This presentation will occur from December 6 to December 9, where leading experts in the field will gather to discuss advancements in blood-related diseases.
Overview of ICT01 and Its Impact
As a first-in-class ?9?2 T-cell activator, ICT01 aims to tackle the pressing challenge of acute myeloid leukemia (AML), particularly in older or unfit patients who have limited treatment options. This initiative showcases the efficacy of cutting-edge treatment combinations, particularly the use of ICT01 alongside azacitidine and venetoclax, which have resulted in promising remission rates.
Details of the Upcoming Presentation
The oral presentation will delve into findings from the EVICTION study, a thorough investigation encompassing both safety and efficacy assessments of ICT01 in AML patients. This study, conducted in multiple stages, uniquely positions ImCheck to contribute significantly to the understanding and treatment of this aggressive disease.
Session Information
The session highlights include:
- Abstract Title: "?9?2 T-cell (?9?2TC) activation with ICT01 and azacitidine-venetoclax induces high rates of remission and overall survival in patients with newly diagnosed AML: Results from the phase 1/2 study EVICTION"
- Presenter: Sylvain GRACIAZ, MD, PhD
- Session: Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies
- Room: OCCC - Chapin Theater (320)
- Date: Sunday, December 7
- Time: 5:15 p.m.- 5:30 p.m. ET
The Significance of the EVICTION Study
The EVICTION trial marks a pivotal moment in cancer research, as it explores the potential of ICT01 for patients who have already undergone various treatments without success. Divided into two distinct parts, the study first evaluates the safety and tolerability of ICT01, followed by an expansion phase assessing its effectiveness in various cancer types.
In-Depth Insights on ICT01
ICT01 harnesses the body's immune response by activating ?9?2 T-cells, which are crucial for identifying and responding to cancer cells. This mechanism not only enhances the immune response but also helps in the migration of these T-cells to tumor sites, leading to more targeted and effective treatment outcomes.
About ImCheck Therapeutics
ImCheck Therapeutics is at the forefront of developing innovative immunotherapeutic antibodies aimed at combating various forms of cancer. With a strong focus on butyrophilins, a new class of immunomodulators, ImCheck is redefining treatment paradigms in oncology, autoimmune, and infectious diseases. Their lead product, ICT01, showcases advancements that highlight the potential for improved survival rates through enhanced immune functionality.
Future Developments and Collaborations
As the company progresses towards late-stage clinical trials, there is an anticipation of groundbreaking results that may outpace conventional therapies. Notably, ImCheck recently entered a share purchase agreement with a leading biotechnology firm, aimed at accelerating the development of its innovative therapies.
Frequently Asked Questions
What is ICT01?
ICT01 is a monoclonal antibody designed to activate ?9?2 T-cells for treating various cancers, particularly acute myeloid leukemia.
When will the ASH presentation take place?
The presentation is scheduled for Sunday, December 7th, 2025, from 5:15 p.m. to 5:30 p.m. ET.
Where can I find more information about the EVICTION study?
Detailed information about the EVICTION study and its results will be available on ImCheck's corporate website after the presentation.
What are the implications of the EVICTION study results?
The study could potentially redefine treatment options for patients with AML, showcasing the effectiveness of ICT01 combined with azacitidine and venetoclax.
Who are the key personnel involved in the presentation?
The presentation will be led by Sylvain GRACIAZ, MD, PhD from Institut Paoli-Calmettes.
